From the monthly archives: June 2012

20/20 vision – in hindsight (TopoTarget)

By On 29. June 2012 · Leave a Comment · In BioPorto, Spectrum, Topotarget

After a hectic day – its time for a little soulsearching. I have no shares in TopoTarget,  but that’s just a coincidence, I might as well have had; but basically I am always a little wary with “one-trick-pony’s “- especially  biotech-ponies  –

Relying on just one product-line is dangerous, it’s 100%  make/break … But after todays […]

Continue Reading →

lidt tanker på bagsmækken (TopoTarget)

By On 29. June 2012 · Leave a Comment · In BioPorto, Spectrum, Topotarget

Her på bagsmækken kan man gøre sig lidt tanker.  Jeg har ingen aktier i TopoTarget, men det kunne såmænd godt have været tilfældet. Jeg er altid lidt bekymret ved one-trick-pony’s – især når det er biotech – det er jo 100% vind eller forsvind … Jeg tror til gengæld alle herinde på MI har godt […]

Continue Reading →

The BioP US patent family, who’s next…

By On 29. June 2012 · Leave a Comment · In BioPorto

Bioporto has filed for more US patents,  all related to measurement of NGAL. One thing strikes you when you look at the various applications.

Take a look for yourself – if at first you don´t see the common denominator  scroll down

 

 

Exclusion patent.

 

The ratio patent:

 

The CutOff patent:

 

scroll […]

Continue Reading →

The Important First US NGAL-patent

By On 27. June 2012 · 1 Comment · In BioPorto

Today BioPorto was granted their first US patent (the ratio patent) . This is truly a milestone… Hip-Hip-Hooray… The Patent is measuring the ratio between NGAL levels in urine and plasma.

Why is this important – you might ask…

A: it is the FIRST US patent – its significance can not be overrated

B: It is […]

Continue Reading →

DKTI & Dandrit merger practically complete

By On 27. June 2012 · Leave a Comment · In DanDrit

Yesterday DKTI made an announcement regarding the ongoing talks with Dandrit A/S. Apparantly the status of DKTI a7s as an investment company raises some tax-issues with regard to the proposed merger.

The solution has therefore been that  Dandrit shareholders get new shares in DKTI A/S (a swap if you will). General Assembly to be held […]

Continue Reading →

Global NGAL Distribution Agreement, when ?

By On 26. June 2012 · 2 Comments · In BioPorto

“When – oh when – will we see a Distribution Agreement ? ”   This must have been the most prominent question on the minds of BioPorto-shareholders this year.

Looking at the debates/discussions/polls here on MI – (The Lesser Evil) it certainly has been the predominant topic (apart from OD and EPO)

One could of […]

Continue Reading →

Biomarkers of Kidney Disease (NGAL et al..)

By On 26. June 2012 · Leave a Comment · In BioPorto

The Title says it all, Biomarkers of Kidney Disease by Charles Edelstein (and a string of noteworthy contributors) is a remarkable book collecting practically all the knowledge available on biomarkers.

For the avid reader of these pages – the book contains new groundbreaking new info – it does however give an excellent summary of the […]

Continue Reading →

Biogaia, we have to start somewhere

By On 25. June 2012 · Leave a Comment · In BioGaia

Biogaia, we have to start somewhere…:)  One of the most interesting companies on the swedish stockexchange is Biogaia. Biogaia is a company that has shown impressive financial results over the last 5 years. Biogaia is working with probiotic bacteria, (Lactobacillus reuteri) – bacteria that helps solve health problems.

Biogaia is working very closely with […]

Continue Reading →

Dandrit, measuring up the competition

By On 25. June 2012 · Leave a Comment · In DanDrit

Dandrit is given a chance to measure up the competition at the  Cancer Vaccine Conference in Boston late june…

Speakers are amongst others: dendreon,  Bristol-Myers Squibb,  Immunovaccine, Novartis, AstraZeneca, all among the top tier cancer vaccine companies of the world

the whole program is available here:

http://medicoinvestor.com/wp-content/uploads/2012/06/agenda.pdf

DanDrit will be represented by Dr. Eric Leire, […]

Continue Reading →

Spectrum June 2012 Chart update

By On 25. June 2012 · Leave a Comment · In Spectrum

I have made an update on the Spectrum Chart.

Pay attention to  the blue line at $15, it could be, that $15 proves to be an area where there is  major resistance !!

Continue Reading →

TopoTarget at a Glance

By On 25. June 2012 · Leave a Comment · In Spectrum, Topotarget

This is TopoTarget at a glance, hopefully this will provide you with an overview of one of the most exiting Biotech companies in Denmark.

Apart from telling you a bit about the investment-opportunity, I (investor89) will also make a laymans explanation of some the abbreviations you will encounter when studying TopoTarget

TopoTarget themselves describe the […]

Continue Reading →
Set your Twitter account name in your settings to use the TwitterBar Section.